Centrus Energy Fair Value Slides Lower as LEU Still Trades Well Above Fundamentals

Valuation is moving lower while LEU still trades at a premium

The fair-value reference point got less generous

Centrus is no longer a case of "great asset, temporary neglect." The valuation bar has moved lower while the stock remains stretched. The latest base-case intrinsic value is $72.72 versus a market price of $185.31, implying shares still trade at roughly 2.5x that fundamental reference point. That is a large premium, not a modest one.

The recent selloff has not closed that gap. LEU is still up 401% year to date and remains well above $72.721 intrinsic value even after falling 51.89% from the October 2025 peak. Investors have shaken out some excess, but not enough to bring price in line with current fair-value estimates.

Why the valuation debate still matters now

Policy support has not disappeared. Washington has kept domestic nuclear fuel production in focus, and bulls can point to the $900 million DOE award and plans for domestic manufacturing. But the strategic story still looks ahead of proven delivery. The more cautious case is straightforward: no official capital budget or planned production rates, continued reliance on TENEX for LEU supply, and execution and cost risk around the Piketon buildout.

That is the core repricing risk. If optimism stays anchored to import-substitution headlines while commercial scale takes longer to arrive, the multiple can compress again.

Better strategy does not automatically raise fair value

Policy support strengthens the thesis first, valuation later

The bullish case has clearly improved. The $900 million DOE award strengthens the national-security angle, and management's plans for domestic manufacturing make the import-substitution thesis more concrete. But investors still appear to be underwriting a strategic outcome, not a fully proven return profile.

That distinction matters. A company can become more strategically important while the stock still looks expensive if execution timelines, capital intensity, or earnings conversion do not keep pace.

What keeps the valuation case cautious

The valuation model cannot fully share the market's enthusiasm because key operating inputs are still missing. Centrus has not provided an official capital budget or planned production rates. Without those, it is harder to underwrite timing, utilization, and when expansion dollars turn into durable earnings.

That is especially relevant with the $5-7 billion Piketon expansion in view. Large projects can stretch ramp times, raise cash-flow timing risk, and leave room for costs to rise before revenue catches up.

Why fair value can still move lower

If the market keeps paying a larger narrative premium than the business earns through execution, fair value can still look too high even as the story improves. For now, investors are paying for strategic relevance and smooth execution, not yet for a mature, self-reinforcing cash engine.

Centrus has shown operating strength, but the stock still looks ahead of fundamentals

The latest quarter supported the bull case

The latest quarter gave bulls real operating evidence. Centrus delivered Q2 revenue of $176.1 million, up 14%, beat GAAP EPS expectations at $0.77 versus $0.71 estimates, and produced a free-cash-flow margin of 33.1%. That weakens the argument that this is only a policy story with no operating backbone.

Price still reflects excitement as much as execution

But strong results alone do not explain the stock move. Before this quarter, LEU had already surged over 70% in a month. That kind of move usually pulls momentum investors in more than fundamental ones. After an advance like that, the market often trades possibility harder than proof.

There is still an income-statement wrinkle to watch. Operating margin was 5.9%, down from 21.7% a year earlier, even as free-cash-flow margin held up. The strategic story appears to be getting richer faster than core operating leverage has been confirmed.

What would justify a higher multiple from here

The recent quarter showed Centrus can still execute at the operating level, with Q2 revenue up 14%, a GAAP EPS beat, and a strong free-cash-flow margin. That keeps the bull case alive. But after a 401% year-to-date surge, another rally likely needs proof that the strategic story is becoming a more disciplined earnings engine, not just a more compelling narrative.

Signals that would support the upside case

• Management provides more operating detail around the $900 million DOE award, planned domestic manufacturing, and the potential for increased backlog growth.
• Centrus shows that new enrichment capacity is translating into real commercial orders rather than only strategic promise.
• The revenue beat and free-cash-flow strength seen in the latest quarter prove repeatable rather than incidental.

Signals that would weaken the premium

• Another delay in defining the Piketon project through an official capital budget or planned production rates would leave execution risk too large for growth multiples.
• Continued sensitivity to TENEX reliance or Russian export-license risk would suggest margins may be more fragile than the market assumes.
• If the stock keeps trading far above base-case intrinsic value without new operational confirmation, optimism still appears to be outrunning evidence.